Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 8/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3546758 | 0.77 | EPHX2 (0.39) | KDM4EPOLBEPHX1ALDH1A1RECQL | |
| SCHEMBL3550648 | 0.73 | ARG1 (0.33) | — | |
| SCHEMBL580695 | 0.72 | ALDH1A1 (0.38) | ALDH1A1 | |
| SCHEMBL2200625 | 0.72 | ALDH1A1 (0.38) | ALDH1A1 | |
| SCHEMBL13846152 | 0.72 | SMN1; SMN2 (0.40) | KDM4EPOLBEPHX1ALDH1A1DPP4 | |
| SCHEMBL3546762 | 0.71 | EPHX1 (0.41) | KDM4EPOLBEPHX1ALDH1A1RECQL | |
| SCHEMBL21088943 | 0.70 | EPHX1 (0.41) | KDM4EPOLBEPHX1ALDH1A1SMN1; SMN2 | |
| SCHEMBL9180645 | 0.70 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL21791674 | 0.70 | KDM4E (0.38) | KDM4EPOLBEPHX1ALDH1A1SMN1; SMN2 | |
| SCHEMBL9184201 | 0.68 | ALDH1A1 (0.35) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709471-B2 | Compounds | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| US-20080009482-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009482-A1 | NOVEL COMPOUNDS | CYP11B2, CYP11B1, CYP46A1 | KDM4E 3977/4885POLB 3906/4885EPHX1 730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.